<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03086759</url>
  </required_header>
  <id_info>
    <org_study_id>CEP UNIFESP 842 167/2014</org_study_id>
    <nct_id>NCT03086759</nct_id>
  </id_info>
  <brief_title>Intra-Articular Platelet Rich Plasm Use in Osteoarthritis of Knee.</brief_title>
  <official_title>Intra-Articular Use of Platelet Rich Plasma Versus Corticosteroid: A Clinical Trials in Osteoarthritis of Knee.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoarthritis of the knee is a very prevalent disease. However, there are few therapeutic
      options for its patients. Platelet-rich plasma is a treatment option for chronic pain. If
      proven to be effective in its intra-articular use, Platelet-rich plasma may help in the
      treatment of these patients.

      Goal:

      Primary objective: To compare effectiveness in improving pain and function and the
      medium-term tolerance (12 weeks) of intra-articular injection of Platelet-rich plasma versus
      intraarticular injection of triamcinolone hexacetonide in patients with symptomatic primary
      knee osteoarthritis.

      Secondary objective: To compare the medium-term effectiveness of intra-articular injection of
      Platelet-rich plasma versus intra-articular injection of triamcinolone hexacetonide to
      improve synovial hypertrophy and quality of life in these patients.

      Methods: A prospective randomized controlled double-blind study with three groups (each with
      n = 33) of patients with symptomatic osteoarthritis of knees who will receive intra-articular
      infiltration in a single moment. Patients will be allocated to one of three groups: 1)
      Platelet-rich plasma group: patients who will receive plasma; 2) triamcinolone hexacetonide
      Group: patients who will receive 40mg of triamcinolone hexacetonide; And 3) Isotonic saline
      solution group: patients who will receive isotonic saline solution. The patients will be
      evaluated by &quot;blind&quot; evaluators in 4 assessment times up to 12 weeks of follow-up through
      clinical assessment instruments (rest and movement pain, joint edema, goniometry, clinical
      improvement scale, quality of life questionnaire as the SF36), functional (Womac
      questionnaire, M. Lequesne Functional Knee Index, 6 min walk test, Time up and go test), and
      ultrasound test (quantitative and semiquantitative measurement of synovial hypertrophy and
      semiquantitative Power Doppler).

      Statistics: The following statistical tests will be used according to the need: Student's t
      test, Mann-whitney, Pearson's chi-square test and ANOVA for repeated measures. A statistical
      significance of 5% will be considered.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2017</start_date>
  <completion_date type="Anticipated">March 2, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain</measure>
    <time_frame>Baseline, after 4, 8, 12 and 56 weeks</time_frame>
    <description>Evaluated using a visual analogue scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in joint edema</measure>
    <time_frame>Baseline, after 4, 8, 12 and 56 weeks</time_frame>
    <description>Evaluated using a visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in range of motion</measure>
    <time_frame>Baseline, after 4, 8, 12 and 56 weeks</time_frame>
    <description>Evaluated using goniometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in a clinical improvement scale</measure>
    <time_frame>Baseline, after 4, 8, 12 and 56 weeks</time_frame>
    <description>Evaluated using an improvement scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Baseline, after 4, 8, 12 and 56 weeks</time_frame>
    <description>Using the SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional capacity</measure>
    <time_frame>Baseline, after 4, 8, 12 and 56 weeks</time_frame>
    <description>Using the WOMAC questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional capacity</measure>
    <time_frame>Baseline, after 4, 8, 12 and 56 weeks</time_frame>
    <description>Using the M Lequesne questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional capacity</measure>
    <time_frame>Baseline, after 4, 8, 12 and 56 weeks</time_frame>
    <description>Using the six minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional capacity</measure>
    <time_frame>Baseline, after 4, 8, 12 and 56 weeks</time_frame>
    <description>Using the time to up and go test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changing in quantitative and semiquantitative measurement of synovial hypertrophy and semiquantitative Power Doppler</measure>
    <time_frame>Baseline, after 4, 8, 12 and 56 weeks</time_frame>
    <description>Using an ultrasound exam</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Platelet rich plasm group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone Hexacetonide group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Isotonic Saline Solution group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>platelet rich plasm</intervention_name>
    <description>intra-articular infiltration with platelet rich plasm</description>
    <arm_group_label>Platelet rich plasm group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Hexacetonide</intervention_name>
    <description>intra-articular infiltration withTriamcinolone Hexacetonide</description>
    <arm_group_label>Triamcinolone Hexacetonide group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Isotonic Saline Solution</intervention_name>
    <description>intra-articular infiltration with Isotonic Saline Solution</description>
    <arm_group_label>Isotonic Saline Solution group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary knee osteoarthritis

          -  degree II and II in Kellgren &amp; Lawrence classification

          -  pain duration: more than three months

          -  pain in the visual analogue scale between 4 and 8cm

          -  agree in participate and sign the consent form

        Exclusion Criteria:

          -  secondary knee osteoarthritis

          -  skin lesion in knee

          -  intraarticular joint injection in the previous three months

          -  steroids use in the previous 30 days

          -  degree I or IV in Kellgren &amp; Lawrence classification

          -  inflammatory arthritis, gout and pseudo-gout

          -  cancer

          -  previous surgery in knee

          -  cardiovascular and respiratory disease that change functional status

          -  pregnancy and breastfeed

          -  coagulation disturb

          -  bacterial infection

          -  handicapped

          -  NSAIDs and Platelet anticoagulant in the previous month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jose Carlos N Tamashiro</last_name>
    <phone>5511983831949</phone>
    <email>jcntamashiro@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universidade Federal de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04023900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Furtado, PhD</last_name>
      <phone>551155764239</phone>
      <email>rvfurtado@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Jose Carlos Nunes Tamashiro</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

